Antwortschreiben der EMA zur Presseanfrage vom 12.02.2023 bzgl. Warnhinweisen

Von: EMA - am: 15.02.2023

Dear Sir,

Overall, what we can say is that the assessment and authorisation of medicines in the EU is robust and guided by high standards of quality, efficacy and safety. Before a vaccine can go onto the market, EMA needs to have robust information on its safety, efficacy and quality. Authorisation will be granted when the evidence shows that the benefits of vaccination are greater than any risks of the vaccine. From all the information we have seen, the benefits of the COVID-19 vaccines far outweigh the risks.

After authorisation, EMA, together with the EU Member States, continues to monitor the safety of the COVID-19 vaccines so that prompt regulatory action can be taken in the event of any identified safety issue. New safety information for all COVID-19 vaccines has been communicated regularly on EMA's website since the vaccines were first authorised for use in the EU and the respective product information for each vaccine has been updated accordingly.

You can read more on the safety of COVID-19 vaccines here.

Kind regards,

EMA press office

European Medicines Agency